Ropes & Gray Advises Teva Pharmaceuticals in Strategic Global Licensing Agreement With MAbxience for Oncology Biosimilar Candidate
April 05, 2024
April 05, 2024
BOSTON, Massachusetts, April 5 -- Ropes and Gray, a law firm, issued the following news:
Ropes & Gray represented Teva Pharmaceuticals International GmbH in a strategic global licensing agreement with mAbxience for a biosimilar candidate currently in development for the treatment of multiple oncology indications.
The transaction was announced on April 4. Financial terms were not disclosed.
Under the licensing agreement, mAbxience will leverage its exper . . .
Ropes & Gray represented Teva Pharmaceuticals International GmbH in a strategic global licensing agreement with mAbxience for a biosimilar candidate currently in development for the treatment of multiple oncology indications.
The transaction was announced on April 4. Financial terms were not disclosed.
Under the licensing agreement, mAbxience will leverage its exper . . .